S. B. Kaye

发表

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer.

I. Vergote, L. Gianni, G. Ross, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers

M. Gore, G. Rustin, H. Gabra, 2008, British Journal of Cancer.

Revisiting the past: utilizing archival tissue for the detection and quantification of gene expression

C. Bunker, S. Kaye, D. Peston, 2009, The British journal of dermatology.

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview.

M. Piccart, M. Aapro, P. Francis, 1997, European journal of cancer.

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

D. Provencher, M. Gore, S. Chan, 2007, British Journal of Cancer.

Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?

N M deSouza, N Tunariu, N. Tunariu, 2012, British Journal of Cancer.

Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck

M. Piccart, J. Wanders, J. Verweij, 1994 .

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

B. Monk, I. Vergote, S. Chan, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

B. Monk, I. Vergote, S. Chan, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer

A. Ashworth, B. Weigelt, C. Poole, 2011, Nature Reviews Clinical Oncology.

Cervical carcinoma: a drug-responsive tumor--experience with combined cisplatin, vinblastine, and bleomycin therapy.

M. Friedlander, S. Kaye, P. Russell, 1983, Gynecologic oncology.

Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)

M. Williams, S. Fosså, D. Dearnaley, 2005, British Journal of Cancer.

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

E. Raymond, R. Kurzrock, G. Schwartz, 2012, British Journal of Cancer.

Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.

R. Glasspool, P. Vasey, S. Kaye, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

Juanita Lopez, U. Banerji, T. Yap, 2017, European journal of cancer.

A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.

M. Piccart, J. Wanders, J. Verweij, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

The integration of docetaxel into first-line chemotherapy for ovarian cancer

S. Kaye, S. B. Kaye, 2001, International Journal of Gynecologic Cancer.

Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT).

M. Ratain, K. Flaherty, M. Gore, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

N. Le bail, G. Catimel, M. Clavel, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers

G. Rustin, H. Gabra, K. Carty, 2008, British Journal of Cancer.

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer

M. Gore, G. Hall, R. Glasspool, 2014, British Journal of Cancer.

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG.

G. Rustin, P. Vasey, Susana Banerjee, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.